# Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct07589543/  
OnCo record `nct07589543` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cyclophosphamide, Fludarabine in ovarian cancer, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT07589543 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUALNK, Cyclophosphamide, Fludarabine. Conditions listed: Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07589543
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of Dual-Target CAR-NK Cells (EB-DUALNK) Following Lymphodepleting Chemotherapy in Adults With Recurrent or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Sponsor: Beijing Biotech
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07589543: https://clinicaltrials.gov/study/NCT07589543

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07589543.json